ID

14354

Beschreibung

Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01226303

Link

https://clinicaltrials.gov/show/NCT01226303

Stichworte

  1. 12.04.16 12.04.16 -
Hochgeladen am

12. April 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Acute Promyelocytic Leukemia NCT01226303

Eligibility Acute Promyelocytic Leukemia NCT01226303

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with a clinical diagnosis of initial apl and subsequently confirmed to have pml-rarα, npm1-rarα or numa-rarα fusion. whilst this study is only for atra-sensitive apl, apl is a hematological emergency and atra should be commenced as soon as the diagnosis is suspected. study entry should not wait until the diagnosis of apl has been confirmed molecularly or cytogenetically
Beschreibung

Acute Promyelocytic Leukemia

Datentyp

boolean

Alias
UMLS CUI [1]
C0023487
less than 21 years of age at initial diagnosis (for aieop, see appendix a)
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
considered suitable for anthracycline-based chemotherapy
Beschreibung

Anthracyclines

Datentyp

boolean

Alias
UMLS CUI [1]
C0282564
Informed Consent
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Negative serum test to rule out pregnancy within 2 weeks prior to registration in females of childbearing potential (non childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized)
Beschreibung

Patient not pregnant

Datentyp

boolean

Alias
UMLS CUI [1]
C0232973
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with a clinical diagnosis of apl but subsequently found to have plzf-rarα
Beschreibung

RARA/ZBTB16 Fusion Protein

Datentyp

boolean

Alias
UMLS CUI [1]
C3537406
fusion or lacking pml-rarα, npm-rarα or numa-rarα rearrangement should be withdrawn from the study and treated on an alternative protocol.
Beschreibung

Retinoic Acid Receptor

Datentyp

boolean

Alias
UMLS CUI [1]
C0140278
refractory/relapsed apl (the guidelines in this protocol for that subgroup are intended for patients treated from initial diagnosis according to this protocol)
Beschreibung

Relapse

Datentyp

boolean

Alias
UMLS CUI [1]
C0035020
concurrent active malignancy
Beschreibung

Malignant Neoplasms

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
Pregnant or lactating
Beschreibung

Pregnant or lactating

Datentyp

boolean

Alias
UMLS CUI [1]
C0549206
UMLS CUI [2]
C2828358
physician and patient/guardian think that intensive chemotherapy is not an appropriate treatment option
Beschreibung

Chemotherapy Regimen

Datentyp

boolean

Alias
UMLS CUI [1]
C0392920
patients who have received alternative chemotherapy for 7 days or longer without atra for any reason (either apl not initially suspected or atra not available).
Beschreibung

Tretinoin

Datentyp

boolean

Alias
UMLS CUI [1]
C0040845

Ähnliche Modelle

Eligibility Acute Promyelocytic Leukemia NCT01226303

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Acute Promyelocytic Leukemia
Item
patients with a clinical diagnosis of initial apl and subsequently confirmed to have pml-rarα, npm1-rarα or numa-rarα fusion. whilst this study is only for atra-sensitive apl, apl is a hematological emergency and atra should be commenced as soon as the diagnosis is suspected. study entry should not wait until the diagnosis of apl has been confirmed molecularly or cytogenetically
boolean
C0023487 (UMLS CUI [1])
Age
Item
less than 21 years of age at initial diagnosis (for aieop, see appendix a)
boolean
C0001779 (UMLS CUI [1])
Anthracyclines
Item
considered suitable for anthracycline-based chemotherapy
boolean
C0282564 (UMLS CUI [1])
Informed Consent
Item
Informed Consent
boolean
C0021430 (UMLS CUI [1])
Patient not pregnant
Item
Negative serum test to rule out pregnancy within 2 weeks prior to registration in females of childbearing potential (non childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized)
boolean
C0232973 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
RARA/ZBTB16 Fusion Protein
Item
patients with a clinical diagnosis of apl but subsequently found to have plzf-rarα
boolean
C3537406 (UMLS CUI [1])
Retinoic Acid Receptor
Item
fusion or lacking pml-rarα, npm-rarα or numa-rarα rearrangement should be withdrawn from the study and treated on an alternative protocol.
boolean
C0140278 (UMLS CUI [1])
Relapse
Item
refractory/relapsed apl (the guidelines in this protocol for that subgroup are intended for patients treated from initial diagnosis according to this protocol)
boolean
C0035020 (UMLS CUI [1])
Malignant Neoplasms
Item
concurrent active malignancy
boolean
C0006826 (UMLS CUI [1])
Pregnant or lactating
Item
Pregnant or lactating
boolean
C0549206 (UMLS CUI [1])
C2828358 (UMLS CUI [2])
Chemotherapy Regimen
Item
physician and patient/guardian think that intensive chemotherapy is not an appropriate treatment option
boolean
C0392920 (UMLS CUI [1])
Tretinoin
Item
patients who have received alternative chemotherapy for 7 days or longer without atra for any reason (either apl not initially suspected or atra not available).
boolean
C0040845 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video